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The intestine serves as both our largest single barrier to the external environment and 
the host of more immune cells than any other location in our bodies. Separating these 
potential combatants is a single layer of dynamic epithelium composed of heteroge-
neous epithelial subtypes, each uniquely adapted to carry out a subset of the intestine’s 
diverse functions. In addition to its obvious role in digestion, the intestinal epithelium is 
responsible for a wide array of critical tasks, including maintaining barrier integrity, pre-
venting invasion by microbial commensals and pathogens, and modulating the intestinal 
immune system. Communication between these epithelial cells and resident immune 
cells is crucial for maintaining homeostasis and coordinating appropriate responses to 
disease and can occur through cell-to-cell contact or by the release or recognition of 
soluble mediators. The objective of this review is to highlight recent literature illuminat-
ing how cytokines and chemokines, both those made by and acting on the intestinal 
epithelium, orchestrate many of the diverse functions of the intestinal epithelium and its 
interactions with immune cells in health and disease. Areas of focus include cytokine 
control of intestinal epithelial proliferation, cell death, and barrier permeability. In addition, 
the modulation of epithelial-derived cytokines and chemokines by factors such as inter-
actions with stromal and immune cells, pathogen and commensal exposure, and diet 
will be discussed.
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iNTRODUCTiON
The intestinal epithelium separates the diverse and ubiquitous members of the intestinal luminal 
microbiome, virome, and mycobiome from the largest population of resident immune cells any-
where in the body, forming our largest single barrier to the external environment (1–4). As such, 
in addition to its critical role in digestion, the gut epithelium is also charged with mediating much 
of the interaction between luminal organisms and immune cells to ensure appropriate defensive 
reactions to pathogens versus tolerance of commensal microorganisms (1).
The physical intestinal barrier consists of a continuous single layer of columnar epithelial cells 
overlain by a variably thick layer of mucus. This mucus layer is embedded with antibodies and 
antimicrobial peptides and physically separates the epithelium from direct contact with much of 
the luminal microbiota (2). The majority of intestinal epithelial cells are absorptive enterocytes, but 
the epithelium also contains a number of more specialized cell types, including Paneth cells (in the 
small intestine only), goblet cells, hormone-secreting enteroendocrine cells, microfold (M) cells, 
and tuft cells (2, 5). Indeed, even these subtypes are too generalized to fully reflect the diversity 
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of intestinal epithelial cells. Recent single-cell sequencing data 
identified two subtypes of tuft cells and subclassified enteroen-
docrine cells beyond the eight subclasses previously reported (6).
The gut epithelium is continuously renewed by Lgr5+ stem 
cells located in the base of the intestinal crypts. Newly formed 
precursor cells differentiate as they migrate away from the crypt 
toward the villus tip in the small intestine or luminal surface 
in the large intestine, where they are expelled into the lumen 
approximately every 4–5 days. The exception to this is Paneth 
cells, which are long-lived and instead move toward the crypt 
base (2, 5). Each cell type plays critical and distinct roles in 
intestinal function. Mucus-secreting goblet cells are crucial 
for maintenance of the luminal mucus layer and increase in 
frequency moving distally along the intestine, peaking at a fre-
quency of approximately 25% of total epithelial cells in the distal 
colon (2). Small intestinal Paneth cells produce antimicrobial 
peptides and also contribute to stem cell maintenance and func-
tion through the production of Wnt3, pro-epidermal growth 
factor, and Notch ligands (2). M cells overlie gut-associated 
lymphoid tissues and facilitate the transport of luminal antigens 
to lymphoid cells, while tuft cells coordinate type 2 immune 
responses to parasites (5, 7, 8). Much of intestinal epithelial 
research, including a portion of that presented herein, has 
focused on the use of colorectal cancer cell lines to elucidate 
gut epithelial function. However, due to the heterogeneity of the 
intestinal epithelium in vivo, observations made from cell lines, 
which are not representative of all gut epithelial cell types, may 
be misleading. Recent advances in three dimensional intestinal 
epithelial organoid cultures, which differentiate into the various 
epithelial cell subtypes seen in vivo, are improving our ability to 
more effectively characterize intestinal epithelial function, and 
many of these studies will be highlighted in this review (9).
The gut-associated lymphoid tissues, including Peyer’s patches 
and isolated lymphoid follicles, are likely the most well-recognized 
portion of the intestinal immune system. However, the entire gut 
is armed with a diverse repertoire of immune cells, which vary 
in location and frequency throughout the length of the intestine 
(2). The majority of these cells function in the lamina propria or 
within the epithelium of the intestinal mucosa. The epithelium 
predominantly hosts T cells, while the lamina propria is home to 
cells of both the adaptive and innate arms of the immune system, 
including T  cells, B  cells, innate lymphoid cells (ILCs), mac-
rophages, dendritic cells, mast cells, and eosinophils (2). Immune 
cells may sense luminal antigens directly when the epithelial bar-
rier is breached or by the extension of transepithelial dendrites, 
as has been observed in macrophages and dendritic cells. The 
intestinal epithelium is uniquely positioned and equipped with a 
cadre of pattern recognition receptors to sense luminal antigens 
and danger signals and relay this information to immune cells (2).
The intestinal epithelium faces the difficult challenge of permit-
ting nutrient absorption and ion movement while maintaining an 
impermeable barrier to microorganisms and antigens in the gut 
lumen. The integrity of the intestinal mucosal barrier is critical 
for health; dysfunction of this barrier has been proposed to con-
tribute to both intestinal and systemic disease, including inflam-
matory bowel disease (IBD) and multiple organ dysfunction 
syndrome (10, 11). Intestinal epithelial cells are linked by three 
types of specialized junctional complexes that attach adjacent 
cells and permit the selective paracellular movement of solutes 
and ions: desmosomes, adherens junctions, and tight junctions 
(10,  11). Desmosomes and adherens junctions predominantly 
serve as physical attachments between cells, while the more api-
cally located tight junctions act as selective semipermeable barriers 
to intercellular spaces (12). Tight junctions are composed of four 
types of transmembrane proteins: junctional adhesion molecules, 
claudins, occludin, and tricellulin. Claudins are a family of pro-
teins that are differentially expressed between tissues and exert 
different effects on paracellular permeability. Claudins critically 
regulate the selectivity of the epithelial barrier by forming charge- 
and size-specific channels between epithelial cells (12). The types 
of claudin proteins within tight junctions determine the perme-
ability of these paracellular channels. For example, claudin-2 and 
claudin-6 have been shown to increase tight junction permeabil-
ity. Intracellular zonula occludens proteins connect tight junction 
transmembrane proteins to cytoskeletal actin/myosin complexes, 
which facilitate opening of the tight junction under specific 
conditions (11, 12).
Cytokines and chemokines, soluble protein mediators criti-
cal for intercellular communication, support intestinal mucosal 
homeostasis but can also be key drivers of intestinal inflammation 
and inflammation-associated damage (1, 10, 13). For example, the 
genetic deletion of interleukin (IL)-10 or IL-2 precipitated sponta-
neous colitis in mice, suggesting that these cytokines are essential 
for colon homeostasis. However, a number of other cytokines, 
including IL-6, tumor necrosis factor (TNF), IL-18, IL-1β, and 
IL-17, are overexpressed in the inflamed intestine and have been 
implicated as contributors to intestinal damage (10). Despite these 
seemingly clear-cut observations, there is strong evidence that the 
traditional labels of pro- and anti-inflammatory are too simplistic 
and perhaps even deceiving when used to describe cytokine 
actions in the intestine. In support of this, clinical trials targeting 
cytokines thought to be predominantly pro-inflammatory in the 
intestine, such as IL-17, failed to induce remission in patients with 
IBD (10, 14). In addition, the literature contains conflicting and 
often equally convincing evidence for both pro- and anti-inflam-
matory actions of specific cytokines in the gut (10, 15). There are 
a number of potential explanations for these conflicting data, such 
as the timing of cytokine action, model system used, cytokine 
concentration, and the method of cytokine administration or 
removal (15–17). As such, cytokine actions should be interpreted 
on a situational basis to gain a more complete understanding of 
their diverse roles in health and disease.
Cytokines and chemokines can positively or negatively affect 
intestinal epithelial barrier integrity, and may be derived from 
resident innate or adaptive immune cells, infiltrating inflamma-
tory cells, or from intestinal epithelial cells themselves (Figure 1) 
(10–12, 18–20). Intestinal epithelial proliferation and cell death 
can be induced or restricted by cytokines (21–23). Concordantly, 
various cytokines help heal the epithelial erosions and ulcerations 
characteristic of severe intestinal inflammation, while others 
exacerbate these lesions (10). Specific cytokines have also been 
shown to regulate opposing epithelial functions under different 
circumstances, for instance, proliferation or cell death (16,  22, 
24–26). In addition, cytokines can directly alter intestinal epithelial 
FiGURe 1 | Cytokines can positively or negatively affect intestinal epithelial barrier integrity by driving or inhibiting critical epithelial cell functions such as proliferation, 
apoptosis, and appropriate epithelial barrier permeability. These cytokines can be derived from resident innate or adaptive immune cells, infiltrating inflammatory 
cells, or from intestinal epithelial cells themselves. Abbreviations: T, T cell; B, B cell; ILC, innate lymphoid cell.
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permeability (27, 28). The permeability of epithelial tight junctions 
may be increased or decreased by cytokine modification of the 
expression or localization of their protein components (11, 12, 27, 
29, 30). Cytokines can also drive phosphorylation of myosin light 
chains, resulting in contraction and opening of tight junctions 
(11). Chemokine production by the intestinal epithelium recruits 
immune cells to areas of inflammation; however, whether this 
means epithelial suicide or survival depends on the inflammatory 
insult. Recruited immune cells may be crucial for defense against 
a pathogen but can perpetuate inflammation in conditions such as 
IBD (31–34). Regardless of mechanism, cytokines and chemokines 
are critical players in the integrity of the intestinal epithelial bar-
rier. The purpose of this review is to highlight recent advances in 
our understanding of how cytokines and chemokines, both those 
made by and acting on the intestinal epithelium, orchestrate many 
of the diverse functions of the intestinal epithelium and its interac-
tions with immune cells in health and disease.
CYTOKiNe ACTiONS ON THe iNTeSTiNAL 
ePiTHeLiUM
Cytokine Stimulation of intestinal 
epithelial Proliferation
Multiple cytokines regulate proliferation of the intestinal epi-
thelium, a function that is crucial for both wound closure and 
replacing cells lost through homeostatic shedding (Figure  2) 
(7, 8, 16, 18, 35–50). Although generally thought to contribute to 
the pathology of IBD, recent studies have shown that TNF, IL-6, 
and IL-17 promote epithelial proliferation (14, 16, 18, 21, 44).
Tumor Necrosis Factor
In murine models of T  cell activation and chronic chemically 
induced colitis, genetic ablation of either TNF or its receptor 
impaired Wnt/β-catenin signaling, resulting in reduced epithe-
lial proliferation and delayed mucosal healing (16). This result 
may seem curious in light of the success of anti-TNF therapy in 
IBD patients; however, the authors offer an explanation for this 
perceived conflict by highlighting the mechanism of action of 
efficacious versus ineffective anti-TNF therapies. Therapeutic 
anti-TNF antibodies reduce inflammation in IBD patients by 
inducing apoptosis in inflammatory cells expressing membrane-
bound TNF (51). By contrast, treatment with a soluble TNF 
receptor, which was ineffective in treating Crohn’s disease, binds 
soluble TNF, which the authors propose blocks the ability of TNF 
to promote mucosal healing (16, 52).
Interleukin-6
Interleukin-6 increased proliferation and stem cell numbers in 
an in vitro model of murine small intestinal epithelial organoids, 
and the crypt epithelial cells also expressed IL-6, suggesting an 
autocrine signaling mechanism. Interestingly, the IL-6 recep-
tor was only present on the basal membrane of crypt Paneth 
cells, making it unclear how IL-6 may affect epithelial cells in 
segments of the intestine lacking Paneth cells, such as the colon 
(18). However, Paneth cell metaplasia can be found in various 
types of colitis, in which case this mechanism of IL-6-facilitated 
epithelial repair could play a role (53). Furthermore, Kuhn 
et al. demonstrated that the early inhibition of IL-6 in murine 
models of bacterial colitis and wounding by biopsy impaired 
colon wound healing by limiting epithelial proliferation. They 
also demonstrated by in  situ hybridization that IL-6 mRNA 
transcripts were enriched within the mucosa surrounding sites 
of intestinal perforation in human patients, suggesting that this 
IL-6-driven mechanism of wound healing may also be important 
in humans. These findings suggest that while Paneth cells may 
be crucial for IL-6-induced epithelial proliferation in the small 
FiGURe 2 | Cytokines may promote or inhibit proliferation of intestinal epithelial cells. Interferon (IFN)-γ may induce or limit intestinal epithelial proliferation based  
on duration of exposure. In addition, specific cytokines may only induce proliferation of certain epithelial subtypes. For example, interleukin (IL)-4 increases tuft  
cell numbers, IL-13 signaling supports increases in tuft and goblet cells, and IL-33 stimulates the expansion of goblet and Paneth cells.
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intestine, other mechanisms exist for IL-6 to drive epithelial 
repair in the colon (45).
Interleukin-17
Similarly, genetic ablation of IL-17 reduced intestinal epithelial 
cell proliferation and worsened dextran sulfate sodium (DSS)-
induced murine colitis (44). Furthermore, IL-17 was shown to 
synergize with fibroblast growth factor 2 (FGF2) to promote 
intestinal healing in this study. FGF2 and IL-17 signaling syner-
gistically activated ERK and induced genes related to tissue repair 
and regeneration in primary murine intestinal epithelial cells. 
The authors demonstrated that the mechanism of this synergy 
depended on Act1, an adaptor molecule that suppresses FGF2 
signaling but is required for IL-17 signaling. When cells were co-
stimulated with IL-17 and FGF2, Act1 was preferentially recruited 
to IL-17 receptors, preventing Act1-mediated suppression of 
FGF2 signaling (44). These findings may offer one explanation 
for the unexpected results of a clinical trial investigating the 
inhibition of the IL-17 receptor as a therapy for active Crohn’s 
disease, in which a disproportionate number of patients actually 
experienced worsening disease with treatment (14).
Interleukin-22
Interleukin-22 increased growth in both human and murine 
intestinal organoids, both by inducing proliferation of the epi-
thelial cells and facilitating stem cell expansion (46). IL-22 was 
also shown to be crucial for stem cell maintenance in  vivo in 
the small intestine in a murine model of methotrexate-induced 
intestinal damage (54). During Citrobacter rodentium infection, 
IL-22 production by CD4+ T  cells was critical for colonic epi-
thelial proliferation and resistance to infection-induced mucosal 
pathology (55).
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Interleukin-36
Induction of IL-36 receptor signaling through any one of its 
ligands, IL-36α, IL-36β, or IL-36γ, induced proliferation of intes-
tinal epithelial cells in in vitro organoid cultures, and mice with 
genetic deletion of the IL-36 receptor were more susceptible to 
chemically induced colitis, demonstrating higher disease activity, 
more severe colon pathology, greater bacterial translocation, and 
decreased survival. Furthermore, administration of a combina-
tion of IL-36α and IL-36γ accelerated wound healing in murine 
colons by increasing proliferation of epithelial cells adjacent to 
the experimental wounds (47).
Interleukin-28A
Similarly, IL-28A [also termed interferon (IFN) λ2] induced 
phosphorylation of signal transducer and activator of transcrip-
tion 1 (STAT1) and proliferation in murine small and large 
intestinal epithelial organoid cultures (39). Mice with global 
knockout of the IL-28A receptor or intestinal epithelial cell-
specific knockout of STAT1 developed more severe oxazolone 
and DSS-induced colitis, and the administration of IL-28A or 
genetic ablation of the IL-28A receptor in mice with induced 
colon wounds improved or delayed wound healing, respectively. 
The authors went further to link their murine models to human 
patients with IBD, demonstrating that both IBD patients and 
mice with colitis showed increased expression of the IL-28A 
receptor on the colon epithelium, as well as higher expression of 
IL-28A by cells within the lamina propria of the colon mucosa. 
Co-labeling of lamina propria cells in IBD patients identified 
dendritic cells as a major source of IL-28A (39).
Interleukin-10
A separate study also highlighted innate immune cells as a 
crucial cytokine source for mucosal healing. In a murine model 
of biopsy-induced colon injury, macrophage-derived IL-10 was 
crucial for optimal wound healing (48). IL-10 mRNA and protein 
were increased at wound sites within 1  day of wounding, and 
IL-10 induced epithelial proliferation by stimulating synthesis 
of Wnt1-inducible signaling protein-1. Interestingly, the absence 
of T and B cells in Rag1−/− mice also used in this study did not 
impair wound closure, further highlighting macrophages as the 
primary source of IL-10 in this model and suggesting that adap-
tive immune cells do not play a crucial role in this mechanism of 
wound healing (48).
IL-13, IL-4, and IL-33 Support the Differentiation  
of Specialized Epithelial Cells
Expansion of tuft cells, a specialized taste-chemosensory sub-
type of the intestinal epithelium, can also be induced by innate 
immune cells. During helminth infection, IL-25 secreted by tuft 
cells activates type 2 ILCs to produce IL-13, which induces the 
differentiation of increased numbers of tuft and goblet cells from 
epithelial progenitor cells (7, 8). IL-4, which shares the common 
receptor subunit IL-4 receptor α with IL-13, can also induce tuft 
cell hyperplasia (49). Mahapatro et al. demonstrated that IL-33 
also directly affected the differentiation of epithelial progenitor 
cells. The constitutive expression of IL-33 in the small intestine 
of mice increased goblet and Paneth cell numbers but did not 
promote the proliferation/differentiation of absorptive entero-
cytes. Challenge of IL-33−/− mice with Salmonella Typhimurium 
demonstrated that IL-33 was critical for microbial defense, as mice 
lacking IL-33 had more severe intestinal damage and a greater 
Salmonella burden associated with decreased numbers of goblet 
and Paneth cells and reduced antimicrobial peptide production 
(50). Similarly, mice with genetic deletion of IL-33 or its receptor 
had decreased numbers of goblet cells and more severe colitis in a 
model of oxazolone-induced intestinal inflammation (17).
Cytokine-induced Proliferation  
and Carcinogenesis
In the absence of wound closure, cytokine-induced intestinal epi-
thelial proliferation may prove to be more deleterious than healing. 
In fact, a number of studies have suggested that cytokines, includ-
ing IL-17, IL-6, IL-22, TNF-α, IL-4, and IL-13, either alone or in 
combination, may promote carcinogenesis in intestinal epithelial 
cells (56–60). Wang et al. demonstrated that IL-17 receptor type 
A (IL-17RA) signaling promoted proliferation of transformed 
colon enterocytes. IL-17RA signaling also induced IL-6 expres-
sion, a cytokine previously associated with colitis-associated 
cancer development (56). The concurrent neutralization of either 
IL-6 and IL-22 or TNF-α and IL-17A inhibited NF-κB or STAT3 
signaling, respectively, and reduced the mitogenic effects of these 
cytokines on human colorectal cancer cells (57). Multiple studies 
have also shown that IL-22 alone can promote colorectal cancer 
progression (58, 59).
Furthermore, both IL-4 and IL-13 may contribute to colon 
cancer progression. IL-4 and IL-13 increased the expression of 
NADPH oxidase 1 in human colon cancer cell lines, which led to 
the production of reactive oxygen species and cellular prolifera-
tion. When examined in resected tissues from patients with colon 
cancer, the authors found increased active NADPH oxidase 1 in 
the tumor tissue relative to the adjacent normal colon tissue, 
leading them to suggest that IL-4/IL-13-driven NADPH oxidase 
1 expression may drive colon carcinogenesis (60).
Cytokine inhibition of intestinal epithelial 
Proliferation
In complement to the plethora of proliferation-inducing cytokines 
detailed earlier, a smaller number of cytokines limit intestinal 
epithelial proliferation (Figure 2) (24, 61–64).
Transforming Growth Factor-β (TGF-β)
Transforming growth factor-β suppressed expression of Survivin, 
a molecule critical for functional cell division in intestinal epi-
thelial progenitor cells (61). Consistent with this finding, genetic 
disruption of TGF-β signaling in intestinal epithelial cells was 
sufficient for the development of invasive colon cancer in the face 
of chronic inflammation in mice (62).
Interferons
In a model of constitutive β-catenin signaling, Katlinskaya et al. 
demonstrated that type I IFNs limit intestinal epithelial prolifera-
tion (63). Concordantly, Tschurtschenthaler et al. characterized 
mice with intestinal epithelial-specific genetic deletion of the 
type I IFN receptor as having increased numbers of small 
FiGURe 3 | Cytokines can induce or prevent apoptosis in intestinal epithelial cells. TNF has been shown to either promote or inhibit intestinal epithelial cell apoptosis 
under different conditions. Abbreviations: IAP, inhibitor of apoptosis protein; IRF1, interferon regulatory factor 1; RIPK1, receptor interacting protein kinase 1; TNF, 
tumor necrosis factor.
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intestinal goblet and Paneth cells, epithelial hyperproliferation, 
and increased tumor burden following tumor induction with 
azoxymethane and DSS (64). Remarkably, the authors were 
able to eliminate the epithelial hyperproliferation and increase 
in tumors by cohousing the type I IFN receptor knockout mice 
with wild-type mice, demonstrating that these knockout-induced 
phenotypes were dependent on the gut microbiota (64).
The effects of the type II IFN, IFN-γ, on the intestinal epi-
thelium vary with length of exposure. The short-term incubation 
of the intestinal epithelial cell line T84 with IFN-γ activated 
β-catenin signaling and induced proliferation of the T84 cells, 
peaking at 24  h. However, extended exposure of the T84 cells 
to IFN-γ induced expression of DKK1, which inhibited Wnt-
β-catenin signaling and reduced proliferation. Interestingly, the 
addition of both TNF-α and IFN-γ enhanced these effects (24).
Damage Control: Cytokine Regulation  
of Apoptosis
While well-regulated apoptosis is essential for the homeostatic 
shedding of enterocytes, any perturbations to this process could 
quickly compromise the intestinal epithelial barrier. Indeed, 
increased apoptosis has been detected in the intestinal epithe-
lium of IBD patients, although it is unclear if this is an initiating 
event in the disease, an effect of inflammation, or some combina-
tion of both (5). Increased intestinal epithelial apoptosis is also a 
consistent feature in critically ill humans and animal models of 
critical illness, such as sepsis. This increase in apoptosis contrib-
utes to intestinal epithelial barrier compromise in critical illness, 
which has been implicated as a critical driver of multiple organ 
dysfunction syndrome (11). Cytokines can induce or inhibit 
intestinal epithelial apoptosis (Figure 3) (16, 22–26, 65–67).
Interferons
Interferons have been shown to induce apoptosis of intestinal 
epithelial cells. Using human colon explant cultures, Jarry et al. 
demonstrated that administration of IFN-α-2a rapidly induced 
IFN-γ production by lamina propria resident T cells and IFN-
γ-dependent epithelial apoptosis, a direct effect of IFN-γ on 
the intestinal epithelium that has been reported previously 
(24, 65, 66). Katlinskaya et al. also demonstrated a role for type 
I IFN in promoting apoptosis of the intestinal epithelium in a 
model of constitutive β-catenin signaling (63).
Tumor Necrosis Factor
In contrast to its ability to promote intestinal epithelial prolifera-
tion, one of the most well-characterized actions of TNF in the 
intestine is its ability to induce epithelial cell death. Injection of 
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mice with TNF results in increased apoptosis of both small and 
large intestinal epithelial cells within 6 h, with a concentration of 
apoptotic cells in the intestinal crypts. Exposure of intestinal epi-
thelial organoids derived from mice with genetic deletion of TNF 
receptors 1 and 2 revealed that while both receptors participated 
in TNF-mediated epithelial apoptosis, TNF receptor 1 signaling 
was predominantly involved. The authors further demonstrated 
that TNF-induced intestinal epithelial apoptosis is regulated by 
the inhibitor of apoptosis protein cIAP1. Inhibition of cIAP1 
by second mitochondrial activator of caspases-mimetic com-
pounds, tumor necrosis factor-related weak inducer of apoptosis 
(TWEAK), or genetic deletion sensitized mice to TNF-induced 
intestinal epithelial apoptosis (22). A separate in  vitro study 
using cancerous and non-cancerous colon epithelial cell lines 
demonstrated that osteopontin reduced TNF-induced apoptosis, 
while the overexpression of IFN regulatory factor 1 increased 
TNF-mediated apoptosis (25). TNF was also implicated as con-
tributing to the pathogenesis of intestinal inflammation in mice 
with conditional knockout of receptor interacting protein kinase 
1 (RIPK1). Full RIPK1 knockout mice die perinatally, but the 
conditional RIPK1 knockout in intestinal epithelial cells in mice 
used in this study resulted in intestinal inflammation and early 
death associated with epithelial cell apoptosis. However, this 
phenotype was rescued by a deficiency in TNF receptor 1, and the 
lack of RIPK1 in in vitro cultured intestinal epithelial organoids 
sensitized the cultures to TNF-induced apoptosis (26).
In lieu of apoptosis, under certain circumstances, cells may 
undergo the pro-inflammatory process of regulated necrosis 
termed necroptosis (68). In addition to its ability to drive apop-
tosis, TNF can also initiate necroptosis of intestinal epithelial cells 
under specific conditions. In a model of conditional knockout of 
caspase 8 in intestinal epithelial cells, Günther et al. demonstrated 
that necroptosis in gut epithelial cells was triggered by TNF-α 
produced by other cells upon bacterial lipopolysaccharide (LPS) 
stimulation, not direct LPS-induced toll-like receptor 4 (TLR4) 
signaling in the epithelium. By contrast, gut epithelial necroptosis 
due to TLR3 ligation in the same model was cytokine-independent 
and directly initiated by TLR3 signaling (69).
In light of the strong evidence for a pro-apoptotic function of 
TNF in the gut, Bradford et al. curiously demonstrated an anti-
apoptotic effect of TNF in the intestinal epithelium. In the murine 
model of T cell activation induced by anti-CD3 antibody injec-
tion used in this study, intestinal epithelial apoptosis is expected 
both acutely at the villus tips and later in the crypts around 24 h 
post-injection. Interestingly, and perhaps counterintuitive to the 
evidence presented herein thus far, administration of anti-CD3 
antibody in TNF−/− mice resulted in a sevenfold increase in crypt 
epithelial apoptosis, suggesting that TNF works to limit epithelial 
apoptosis in this model (16). Other studies have also characterized 
an anti-apoptotic role for TNF in the intestinal epithelium, and 
the authors suggest that the level of TNF may determine whether 
it acts to promote or prevent apoptosis, with higher levels of TNF 
proposed to be pro-apoptotic (16, 67).
Transforming Growth Factor-β1
Transforming Growth Factor-β1 can also inhibit intestinal 
epithelial cell death. TGF-β1 reduced apoptosis and prevented 
necrosis in rat jejunal crypt epithelial cells exposed to the TcdA 
toxin of Clostridium difficile (23).
Cytokine Reinforcement of intestinal 
epithelial Barrier integrity
Appropriate permeability of the intestinal epithelium is crucial 
for the balance between nutrient absorption and pathogen exclu-
sion, and a number of cytokines positively affect this epithelial 
function (Figure 4) (12, 17, 27, 42, 70–72).
Interleukin-17
Inhibition of IL-17 receptor A by antibody neutralization wors-
ened disease in the multidrug resistance-1a-ablated (Abcb1a−/−) 
murine model of colitis and was associated with increased epithe-
lial permeability as detected by increased serum concentrations 
of soluble CD14 and LPS binding protein and increased plasma 
concentrations of orally administered sucralose, lactulose, and 
mannitol (70). Lee et al. also demonstrated that a loss of IL-17 
signaling increased intestinal epithelial permeability by showing 
increased amounts of orally administered fluorescein isothiocy-
anate (FITC)–dextran in the serum of mice with both chemically 
induced and T cell transfer-induced colitis in which IL-17 was 
removed by antibody neutralization or genetic deletion (27). The 
authors attributed the increase in gut epithelial permeability in 
the absence of IL-17 to disruptions in the structure of tight junc-
tions, junctional complexes which are critical to the selectivity 
inherent in appropriate gut barrier permeability. The absence 
of IL-17 resulted in the intracellular mislocalization of the tight 
junction complex protein occludin and a loss of co-localization of 
occludin with F-actin. To provide more support for this mecha-
nism, the authors applied TNF-α, a cytokine previously reported 
to disrupt tight junctions and increase epithelial barrier perme-
ability, to cultured Caco-2 cells with or without co-stimulation 
with IL-17A (27, 28). Consistent with their observations in vivo, 
TNF-α altered the intracellular localization of occludin; however, 
co-stimulation with IL-17A reduced the TNF-induced occludin 
mislocalization (27). Along with the previously described ability 
of IL-17 to induce intestinal epithelial regeneration, the ability 
of IL-17 to reinforce the intestinal epithelial barrier offers an 
additional potential explanation for the worsening of Crohn’s 
disease observed in clinical trial patients treated with an antibody 
to inhibit IL-17 receptor signaling (14).
Interleukin-10
Multiple studies have shown the positive effects of IL-10 signaling 
in the gut epithelium for maintenance of appropriate epithelial 
permeability (42, 73, 74). Stimulation of T84 cell monolayers 
with IL-10 restored transepithelial electrical resistance disrupted 
by compromise of the monolayers by incubation with IFN-γ. In 
addition, knockdown of the IL-10 receptor 1 in human intestinal 
epithelial cell lines impaired barrier formation as assessed by 
transepithelial electrical resistance and increased paracellular 
flux (42). These changes suggest alterations in the function of 
intercellular tight junctions owing to the lack of IL-10 signaling; 
however, this potential mechanism was not explored in this study. 
In the same study, mice with intestinal epithelial cell-specific 
FiGURe 4 | Appropriate permeability of the intestinal epithelium maintains balance between nutrient absorption and pathogen exclusion. Cytokines may reinforce or 
impair the intestinal barrier by altering permeability of the epithelium. Epithelial tight junction permeability may be increased or decreased by cytokine modification of 
the expression or localization of tight junction protein components, such as various claudins, occludin, or zonula occludens protein-1 (ZO-1). Cytokines can also 
drive phosphorylation of myosin light chains, resulting in contraction and opening of tight junctions. Interferon (IFN)-γ increases intercellular adhesion molecule-1 
(ICAM-1) expression, and subsequently, ICAM-1-mediated adherence of neutrophils to gut epithelial apical membranes. Neutrophil ligation of ICAM-1 drives the 
phosphorylation of myosin light-chain kinase (MLCK), resulting in actin reorganization leading to increased paracellular permeability and neutrophil transepithelial 
migration.
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knockout of the IL-10 receptor 1 developed more severe chemi-
cally induced colitis with increased epithelial permeability to 
FITC–dextran (42). The authors concluded that the more severe 
colitis in these mice was driven by increased barrier permeability 
due to a lack of IL-10 signaling in epithelial cells. However, as 
previously discussed, IL-10 can induce proliferation in intestinal 
epithelial cells (48). As such, the inhibition of IL-10-induced 
epithelial restitution could have also contributed to the more 
severe colitis demonstrated in mice lacking intestinal epithelial 
expression of the IL-10 receptor 1 in this study.
In a separate study, Zheng et al. demonstrated how a cytokine, 
in this case IL-10, can interact with the intestinal microbiota to 
regulate epithelial function (73). Butyrate, a short chain fatty acid 
made by the intestinal microbiota in  vivo, induced the expres-
sion of both IL-10 receptor α subunit mRNA and protein in T84 
and Caco-2 cells. Treatment of T84 cells with butyrate and IL-10 
increased epithelial barrier integrity more than butyrate alone as 
determined by increased transepithelial electrical resistance. Based 
on the increased expression of the IL-10 receptor α subunit in the 
epithelial cells due to butyrate treatment, the mechanism for this 
increase in barrier integrity owing to butyrate and IL-10 could be 
hypothesized to be an increase in IL-10 signaling due to increased 
IL-10 receptor expression. However, the authors did not compare 
these data with the transepithelial electrical resistance induced by 
IL-10 in the absence of butyrate. As a result, it is unclear from these 
data whether butyrate and IL-10 synergistically increase transepi-
thelial electrical resistance in intestinal epithelial cells, or if the level 
reported in this study could have been induced by IL-10 alone. The 
authors went further to demonstrate that butyrate reduced both the 
mRNA and protein expression of the pro-permeability tight junc-
tion protein claudin-2 in T84 cells in an IL-10 receptor α-dependent 
manner, providing a potential mechanism for the observed 
increases in epithelial barrier integrity in the presence of butyrate 
(73). Interestingly, reductions in butyrate-producing bacteria have 
been reported in the microbiota of ulcerative colitis patients, sug-
gesting a potential mechanism of epithelial barrier compromise due 
to dysbiosis as a contributing factor in this disease (75).
A study by Lorén et al. demonstrated how IL-10 can increase 
the effectiveness of other therapies (74). Previous work by this 
group correlated low IL-10 mRNA levels with poor glucocorticoid 
response in active Crohn’s disease. In a later study, the authors 
discovered a possible mechanism for this observation, as treat-
ment with a combination of IL-10 and glucocorticoids, but neither 
treatment alone, restored the transepithelial electrical resistance of 
Caco-2 cell monolayers following their disruption with TNF-α (74).
Interleukin-6
A study by Kuhn et al. provided more evidence for the crucial rela-
tionship between the microbiota, immune system, and intestinal 
epithelial barrier (71). Bacteria in the order Bacteroidales were 
sufficient to induce localization of intraepithelial lymphocytes in 
the colons of mice, and these cells were an important source of 
IL-6. IL-6 supported epithelial barrier function, as IL-6−/− mice dis-
played reduced expression of the tight junction protein claudin-1, a 
thinner mucus gel layer, and augmented paracellular permeability, 
all defects which were resolved by the transfer of IL-6+/+ intraepi-
thelial lymphocytes to affected mice (71).
Stem Cell Factor
C-kit signaling has also been shown to promote intestinal epi-
thelial barrier integrity through the regulation of a tight junction 
protein. The overexpression of c-kit or administration of its 
ligand stem cell factor increased expression of the tight junction 
protein claudin-3 in colorectal cancer cells in vitro, and decreased 
claudin-3 expression was observed in the colon epithelium of 
mice lacking functional c-kit (72).
Interleukin-33
Rectal biopsies from adult and pediatric patients with ulcerative 
colitis have increased IL-33 expression relative to specimens lack-
ing inflammation (17). To determine if this implicates IL-33 as a 
contributor to inflammation or an anti-inflammatory response 
in these patients, Waddell et al. investigated the role of IL-33 in 
chemically induced colitis in mice (17). Mice with genetic deletion 
of ST2, the receptor for IL-33, had decreased colon transepithelial 
electrical resistance and increased permeability to FITC–dextran, 
suggesting that IL-33 promotes colon epithelial barrier function. 
In support of these data, genetic deletion of either ST2 or IL-33 
precipitated more severe chemically induced colitis in these 
mice (17). However, the authors did not fully characterize the 
mechanism by which IL-33 promoted epithelial barrier integrity 
in these studies. The authors reported that intestinal epithelial 
proliferation and apoptosis were unaffected by the absence of IL-33 
or ST2 in this model of colitis, but that goblet cell numbers and 
Muc2 expression were decreased in these mice. This suggests that 
alterations in the mucus layer could have influenced epithelial bar-
rier permeability in these mice, but the mucus layer itself was not 
evaluated. In addition, potential effects of IL-33 on interepithelial 
junctional complexes were not assessed; however, the authors did 
demonstrate that IL-33-induced augmentation of transepithelial 
electrical resistance in T84 cell monolayers was dependent on 
ERK1/2 signaling (17). This is particularly curious in light of a 
recent paper that reported reduced transepithelial electrical resist-
ance and claudin-1 expression induced by IL-33-stimulated ERK 
signaling in human keratinocytes (76). This discrepancy could be 
explained by the different cell types investigated; however, conflict-
ing roles for IL-33 in intestinal inflammation have been reported. 
Other investigators have demonstrated exacerbation of multiple 
models of murine colitis and decreased intestinal epithelial barrier 
integrity due to the administration of IL-33 (77, 78). Waddell et al. 
suggest that these inconsistencies could be due to differences in 
IL-33 concentrations among studies or the differing characteristics 
of inflammation in each colitis model, two reasonable explanations 
that warrant further investigation (17). In support of the data 
reported by Waddell et al., Sattler et al. demonstrated the induc-
tion of protective IL-10-producing regulatory B  cells by IL-33 
(78). The administration of IL-33 accelerated spontaneous colitis 
in IL-10-deficient mice but did not induce intestinal inflamma-
tion in wild-type mice. In addition, the transfer of IL-33-induced, 
IL-10-producing regulatory B cells to IL-10-deficient mice reduced 
colitis severity and delayed disease onset (78). As previously 
discussed, IL-10 promotes epithelial barrier integrity (42, 73). As 
such, reduced IL-10 production owing to genetic ablation of IL-33 
signaling is a potential mechanism for the increased intestinal 
epithelial permeability observed by Waddell et al. (17, 42, 73).
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Falling Through the Cracks: Cytokine 
Promotion of intestinal epithelial 
Permeability
In contrast to the barrier reinforcing properties of the cytokines 
described earlier, a handful of cytokines can also disrupt the 
intestinal epithelium and promote barrier permeability (Figure 4) 
(29, 30, 79, 80).
Tumor Necrosis Factor
Various effects of TNF-α on the intestinal epithelium discussed 
herein could disrupt the epithelial barrier; however, TNF-α 
stimulation of intestinal epithelial cells has also been specifically 
demonstrated to decrease the protein expression of the tight junc-
tion proteins claudin-1, occludin, and zonula occludens protein-1 
(ZO-1), as well as to induce cytoskeletal F-actin rearrangement 
and the mislocalization of occludin and ZO-1 (29, 30). Multiple 
studies have identified mechanisms to reduce TNF-α-induced 
epithelial barrier compromise, including the overexpression of 
anterior gradient protein 2 homolog, rebeccamycin treatment, and 
the stimulation of muscarinic cholinoceptor-mediated signaling 
(29, 30, 81).
Interleukin-22
Interleukin-22 also increases gut epithelial permeability via 
manipulation of tight junction protein expression. IL-22 stimu-
lation of Caco-2 cells in vitro and murine colon epithelial cells 
in  vivo increased the expression of the tight junction protein 
claudin-2, which forms cation channels. Caco-2 monolayers 
treated with IL-22 displayed decreased transepithelial electrical 
resistance, indicating increased paracellular ion permeability, but 
no change in movement of uncharged macromolecules across the 
monolayers was observed (79).
Interferon-γ
The increase in intestinal epithelial permeability induced by IFN-γ 
described by Sumagin et al. provides an elegant example of the 
intricate relationships between cytokines, the epithelium, and 
immune cells (80). Using the T84 intestinal epithelial cell line 
for an in vitro model of transepithelial migration of neutrophils, 
the authors demonstrated that IFN-γ induced expression of 
the intercellular adhesion molecule-1 (ICAM-1) on the apical 
membrane of T84 cells and increased the number of neutrophils 
adherent to the apical epithelial membranes via ICAM-1 post-
migration. The ligation of ICAM-1 by neutrophils resulted in 
the phosphorylation of myosin light-chain kinase and a subse-
quent increase in epithelial permeability characterized by actin 
cytoskeletal reorganization, paracellular FITC–dextran flux, and 
a decrease in transepithelial electrical resistance. Notably in this 
model, this increase in epithelial permeability facilitated neutrophil 
transepithelial migration (80).
Additional Cytokine effects on intestinal 
epithelial Function
In addition to those detailed earlier, cytokines modulate a wide 
array of other intestinal epithelial functions. While endogenous 
type III IFN produced by intestinal epithelial cells does not restrict 
human rotavirus replication due to viral antagonism of the type 
III IFN response, treatment of human rotavirus-infected small 
intestinal organoid cultures with exogenous type I IFN, and to a 
lesser extent exogenous type III IFN, limits rotaviral replication 
(82). However, other studies in mice have found that IFN-λ, a 
type III IFN, is more effective than type I IFNs in limiting viral 
replication in the intestinal epithelium in models of reovirus and 
rotavirus infection (83, 84).
In a somewhat unexpected role, IL-22 production by neutro-
phils in chemically induced murine colitis induced the expression 
of antimicrobial peptides by the colon epithelium and protected 
the epithelium from chemically induced damage (85). Epithelial 
signaling of the IL-17 receptor regulates colonization of the 
murine intestine with segmented filamentous bacteria through 
the epithelial expression of the apical NADPH oxidase Nox1, 
polymeric immunoglobulin receptor (Pigr), and α-defensins (86). 
In addition to the functions previously discussed, TNF stimula-
tion of the intestinal epithelium has also been shown to reduce 
expression of the Cl HCO3
− −/  exchanging solute carrier family 
26 member 3, which may represent a therapeutic target in IBD-
associated diarrhea (87). TNF also augmented receptor activator 
of NF-κB ligand-induced M cell differentiation (88).
TALKiNG BACK: iNTeSTiNAL ePiTHeLiAL-
DeRiveD CYTOKiNeS AND CHeMOKiNeS
Pro- and Anti-inflammatory Functions  
of intestinal epithelial-Derived Cytokines
The intestinal epithelium is not simply beholden to respond to 
immune cell-derived cytokines but is a rich source of cytokines 
and chemokines, which may ameliorate or promote inflamma-
tion. The colonic epithelium was found to be a larger source 
of trefoil factor 2 (TFF2) than colon leukocytes, and TFF2 was 
protective in both acute and chronic models of DSS-induced 
colitis (19). In models of helminth infection, production of IL-25 
by intestinal epithelial tuft cells regulated the helminth-induced 
type 2 immune response and facilitated worm expulsion (7, 49).
Intestinal epithelial cells also produce the anti-inflammatory 
cytokine IL-10, which likely contributes to tolerance to commen-
sal bacteria. TLR4 ligation induced intestinal epithelial cell expres-
sion of IL-10, and this expression was enhanced by co-culture with 
macrophages (20). As previously discussed, IL-10 has been shown 
to stimulate intestinal epithelial cell proliferation and reinforce the 
integrity of the epithelial barrier (42, 48, 73). Thus, the microbiota 
may contribute to intestinal epithelial integrity through epithelial 
TLR4 ligation and the subsequent autocrine action of epithelial-
derived IL-10. If so, IL-10 would not be the only cytokine with an 
autocrine mechanism for promoting epithelial homeostasis. IL-6 
production by the intestinal epithelium has also been detected, 
which was shown to act in an autocrine manner to regulate crypt 
homeostasis (18).
In contrast to these anti-inflammatory and homeostatic 
effects, intestinal epithelial products may also promote inflam-
mation. The accumulation of visceral fat has been associated with 
chronic intestinal inflammation, and in support of this, coculture 
of intestinal epithelial cells with differentiated adipocytes induced 
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epithelial expression of TNF and matrix metalloproteinase-9 (89). 
IL-1α release by necrotic intestinal epithelial cells in a murine 
model of chemically induced colitis induced cytokine produc-
tion by mesenchymal cells and reactivated colon inflammation 
post-recovery when delivered via enema (90). The findings of 
Bersudsky et al. support these data, as genetic ablation of IL-1α 
ameliorated murine DSS-induced colitis (91).
Intestinal epithelial cells also secrete IL-33; however, there is 
conflicting evidence in the literature regarding its role in both 
IBD [reviewed by Griesenauer et al. (40)] and intestinal carcino-
genesis. IL-33 expression was found to be increased in epithelial 
cells of both murine and human intestinal tumors, and IL-33 
promoted tumor development in ApcMin/+ mice (92, 93). Similarly, 
the expression of IL-33 by intestinal epithelial cells was increased 
in the murine azoxymethane/DSS model of colon cancer, and the 
authors went further to demonstrate that the epithelial expression 
of IL-33 was driven by epidermal growth factor (94). By contrast, 
knockdown of the IL-33 receptor, ST2, in colon cancer cells from 
mice enhanced tumor growth, suggesting a potential antitumori-
genic role for IL-33 (95).
Calling in the Troops: intestinal epithelial 
Chemokine Production
Intestinal epithelial-derived chemokines can contribute to both 
cellular defense and pathology. Listeria monocytogenes infection 
of an intestinal epithelial cell line induced expression of the 
chemokines IL-8, CCL1, and CCL20. Consistent with the epithe-
lial invasiveness of L. monocytogenes, the high levels of CCL20 
and IL-8 were likely induced by intracellular TLR10 signaling, the 
knockdown of which reduced chemokine levels more than silenc-
ing of TLR1 or TLR2 (31). IL-8, CCL1, and CCL20 are responsible 
for neutrophil, Th2 and regulatory T cell, and Th17 and dendritic 
cell trafficking, respectively, and would promote the infiltration 
of these cell types in the infected mucosa (96). Interestingly, a 
separate study identified a non-chemotactic role for IL-8 in the 
intestine. Apically secreted intestinal epithelial cell-derived IL-8 
in response to TLR2 and TLR5 ligation was shown to act in an 
autocrine manner to promote gene expression related to cellular 
differentiation (97).
Chemokines likely play a critical role in the perpetuation of 
intestinal inflammation in IBD patients. Dent et al. reported that 
cocultured eosinophils and intestinal epithelial cells synergized to 
increase neutrophil chemotactic activity and CXCL5 production; 
however, the authors did not quantify the individual contributions 
of each cell type to this increase (33). As evidence of activated 
eosinophils has been detected in acute flares of IBD, this could 
contribute to excessive neutrophil recruitment to the intestine 
and increased tissue damage in active IBD (33). Production of 
the cytokine IL-34 is increased in the intestine of patients with 
active IBD, and Franzè et al. demonstrated that production of the 
chemokine CCL20 was associated with IL-34 signaling in both 
the DLD-1 colon epithelial cell line and in mucosal explants from 
IBD patients (34). CCL20 production could fuel the inflammatory 
response in active IBD patients through the recruitment of Th17 and 
dendritic cells. However, the potential consequences of increased 
CCL20 production are not so clear-cut. In fact, these cells could 
aid in restitution of the epithelial barrier in IBD patients. As noted 
previously, IL-17 can increase intestinal epithelial cell proliferation 
and reduce barrier permeability, and dendritic cells are a critical 
source of IL-28A in the gut, another cytokine shown to induce 
intestinal epithelial proliferation (27, 39, 44, 70). Conversely, this 
hypothesized cytokine-induced proliferation could be too much of 
a good thing. IL-17 has been shown to both induce the prolifera-
tion of transformed enterocytes and stimulate IL-6 production, a 
cytokine implicated in colitis-associated carcinogenesis (56). The 
neutrophil chemokine CXCL1 has also been shown to promote car-
cinogenesis. The upregulation of CXCL1 by colon tumor epithelium 
was dependent on hypoxia-inducible factor 2α and contributed to 
colon carcinogenesis through neutrophil recruitment (32).
intestinal epithelial Responses  
to Pathogens and Commensals
The intestinal epithelium is uniquely located to be the ideal first 
line of defense or communication with intraluminal bacteria 
and viruses. A number of bacteria alter cytokine production by 
the gut epithelium (Figure 5) (98–103). Exposure of the colon 
epithelial cell line HCT-8 to Shiga toxin 2 produced by Shiga-
toxigenic Escherichia coli increased protein expression of IL-8 and 
TNF-α. However, HCT-8 exposure to subtilase cytoxin produced 
by the same bacterium decreased protein expression of IL-8 and 
monocyte chemoattractant protein-1 relative to unstimulated 
control cells, suggesting that these bacteria may use specific toxin 
production to differentially modulate host defenses (98). Infection 
of Caco-2 monolayers with Shigella flexneri 2a or Shigella dysente­
riae 1 induced IL-8 secretion, which was predominantly released 
from the basolateral aspect of the epithelial cells, and Salmonella 
enterica serovar Typhimurium activated non-canonical inflam-
masome activity in murine and human intestinal epithelial cells, 
facilitating IL-18 secretion and bacterial clearance (99, 100).
In contrast to these predominantly pro-inflammatory responses, 
stimulation of Caco-2 cells with commensal bacteria increased 
thymic stromal lymphopoietin (TSLP), IL-8, and TGF-β1 secre-
tion, which resulted in the promotion of a tolerogenic dendritic 
cell phenotype by TSLP and TGF-β1 (101). In addition, probiotic 
bacterial strains have been shown to reduce gut epithelial produc-
tion of IL-8 (102, 103).
Intestinal epithelial cytokine release prompted by viral 
infection can help clear infection or create pathology. Simian 
immunodeficiency virus infection of the intestinal epithelium of 
rhesus macaques induced IL-1β expression by Paneth cells before 
the induction of an antiviral IFN response. IL-1β expression was 
correlated with epithelial disruption characterized by the mis-
localization and reduced expression of tight junction proteins, 
although these changes did not correspond to any aberrant 
responses to bacteria (104).
Multiple studies have documented the production of IFN-λ 
by virus-infected intestinal epithelial cells, although the ability 
of this cytokine to limit viral infection varied between studies 
(82, 84, 105). A possible explanation for these discrepancies may 
be found in the work of Hernández et al., which demonstrated 
that group 3 ILC-derived IL-22 amplified IFN-λ signaling in 
intestinal epithelial cells, and synergistic signaling by the two 
cytokines was necessary for a reduction in viral replication and 
optimal stimulation of IFN-induced gene expression (105).
FiGURe 5 | Pathogens, commensal bacteria, and probiotics can increase or diminish the production of cytokines and chemokines by the intestinal epithelium. 
These interactions may promote or deter immune cell infiltration of the gut, such as by increasing or reducing the production of chemokines, including interleukin 
(IL)-8 and monocyte chemoattractant protein-1 (MCP-1). In some cases, bacterial interactions with the gut epithelium may instruct the intestinal immune system.  
For example, intestinal epithelial cells produce thymic stromal lymphopoietin (TSLP) and transforming growth factor-β (TGF-β) 1 in response to commensal bacteria, 
inducing a tolerogenic phenotype in dendritic cells.
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Dietary Modulation of intestinal epithelial 
Mediator Release
Diet has been implicated as a possible contributing factor to 
IBD; however, research has failed to identify the “ideal” anti-
inflammatory diet for IBD patients (106). Nevertheless, recent 
studies have identified anti-inflammatory effects of specific 
dietary components on the intestinal epithelium. Pretreatment 
of Caco-2 cells with the plant-derived flavonoid cyanidin-
3-glucoside (C3G) reduced TNF-α-induced gene expression of 
IL-8 and TNF-α. C3G also inhibited endothelial cell activation 
and subsequent leukocyte adhesion stimulated by coculture with 
TNF-α-stimulated Caco-2 cells (107). Similarly, treatment of 
Caco-2 cells with the dietary fiber guar gum increased expression 
of the suppressor of cytokine signaling-1 (SOCS-1) and reduced 
TNF-α-induced IL-8 expression. In addition, guar gum adminis-
tration to mice with chemically induced enteritis reduced disease 
activity and pro-inflammatory cytokine expression in the small 
intestine concurrent with an increase in SOCS-1 protein (108).
CONCLUDiNG ReMARKS
Cytokines and chemokines are critical for intestinal epithelial 
homeostasis and responses to disease. The ability of cytokines 
to directly facilitate or restrict intestinal epithelial proliferation, 
apoptosis, and permeability makes them key players in the main-
tenance, or at times destruction, of the intestinal epithelial barrier. 
Furthermore, the release of cytokines and chemokines by the 
intestinal epithelium in response to pathogens, commensal organ-
isms, interactions with other cell types, and dietary compounds 
allows these cells to have critical input into their microenviron-
ment. Despite our frequent tendency to classify cytokines as either 
pro- or anti-inflammatory, we must realize that these labels fail 
to acknowledge the incredible diversity and situational basis of 
cytokine functions. While undoubtedly complex, the cytokine 
biology of intestinal mucosal immunology is a fascinating oppor-
tunity for investigations into both intestinal immunophysiology 
and potential translational approaches to modulate this physiol-
ogy for much-needed novel therapies for intestinal disease.
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